CEFTRIAXONE SODIUM FOR INJECTION BP POWDER FOR SOLUTION

Country: Kanada

Lingwa: Ingliż

Sors: Health Canada

Ingredjent attiv:

CEFTRIAXONE (CEFTRIAXONE SODIUM)

Disponibbli minn:

SANDOZ CANADA INCORPORATED

Kodiċi ATC:

J01DD04

INN (Isem Internazzjonali):

CEFTRIAXONE

Dożaġġ:

2G

Għamla farmaċewtika:

POWDER FOR SOLUTION

Kompożizzjoni:

CEFTRIAXONE (CEFTRIAXONE SODIUM) 2G

Rotta amministrattiva:

INTRAMUSCULAR

Unitajiet fil-pakkett:

5.6ML/8ML(IM)-20.5ML(IV)

Tip ta 'preskrizzjoni:

Prescription

Żona terapewtika:

THIRD GENERATION CEPHALOSPORINS

Sommarju tal-prodott:

Active ingredient group (AIG) number: 0117292006; AHFS:

L-istatus ta 'awtorizzazzjoni:

APPROVED

Data ta 'l-awtorizzazzjoni:

2018-03-15

Karatteristiċi tal-prodott

PRODUCT MONOGRAPH
INCLUDING PATIENT MEDICATION INFORMATION
PR CEFTRIAXONE SODIUM FOR INJECTION BP
Sterile Powder for Solution, 250 mg, 1 g, 2 g and 10 g ceftriaxone per
vial
Intravenous or Intramuscular
BP
Antibiotic
Sandoz Canada Inc.
110 Rue de Lauzon
Boucherville, (Québec), Canada
J4B 1K6
Date of Initial Authorization:
August 17, 2006
Date of Revision:
January 6, 2022
Submission Control Number: 255080
Ceftriaxone Sodium for Injection BP
Page 2 of 58
RECENT MAJOR LABEL CHANGES
7 Warnings and Precautions
01/2022
TABLE OF CONTENTS
SECTIONS OR SUBSECTIONS THAT ARE NOT APPLICABLE AT THE TIME OF
AUTHORIZATION ARE NOT LISTED.
TABLE OF CONTENTS
.................................................................................................................
2
PART I: HEALTH PROFESSIONAL INFORMATION
............................................................................
4
1
INDICATIONS.....................................................................................................................
4
1.1
P
EDIATRICS
.........................................................................................................................
5
1.2
G
ERIATRICS
.........................................................................................................................
5
2
CONTRAINDICATIONS
........................................................................................................
5
4
DOSAGE AND
ADMINISTRATION..........................................................................................
5
4.1
D
OSING
C
ONSIDERATI ONS
.......................................................................................................
5
4.2
R
ECOMMENDED
D
OSE AND
D
OSAGE
A
DJUSTMENT
...........................................................................
6
4.3
R
ECONSTI TUTI ON
..................................................................................................................
7
4.4
A
DMINISTRATION
.....................................................................................